Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice.

While the medium dose did not reach statistical significance ( P < 0.05, two-sided Mann–Whitney U test), there was nevertheless a numerical reduction in comparison to the vehicle group.

also in 59,377 other papers